BrainsGate

BrainsGate operates at the intersection of medical devices, neurotechnology, and therapeutics, with a focused approach to acute ischemic stroke rather than a broad portfolio of hospital devices. Its core differentiation is the use of electrical stimulation of the Spheno-Palatine Ganglion, or SPG, to increase cerebral blood flow. The company’s ISS device is designed around a miniature electrode implanted in the roof of the mouth through a minimally invasive, local-anesthesia procedure comparable to dental treatment. This approach targets a physiological mechanism distinct from conventional clot-removal or drug-based stroke interventions. Medtronic and Boston Scientific appear in BrainsGate’s broader investor or strategic ecosystem, but their presence should not be interpreted as evidence that they compete directly with BrainsGate’s stroke product. BrainsGate’s market position is therefore best characterized as a specialized, clinically oriented neurostimulation developer with meaningful historical financing, but with regulatory risk following the December 2021 FDA advisory outcome and limited publicly visible commercialization evidence.

BrainsGate followed a long venture-backed clinical development path, raising $4 million in a Seed round on Jul 15, 2002, $7 million in a 2005 Venture Round, and $27.5 million in a 2008 Series C. A further $20 million Series C was announced on Aug 1, 2011, followed by $26 million in a 2015 Venture Round and $14 million in Series F financing on Dec 6, 2020. The six rounds total $98.5 million, indicating sustained capital support over 18 years. Product development progressed from the SPG stimulation platform to the ISS device and the ImpACT-24b randomized, double-blind, sham-controlled study for stroke patients treated within a 24-hour window. The December 2021 FDA advisory vote against the device represents the clearest inflection point in the trajectory, creating a substantial barrier to market entry despite the company’s prior clinical investment. BrainsGate is listed as active and has an estimated employee band of 11-50, but there is no documented hiring momentum, product commercialization milestone, or new financing after 2020 in the available profile.